Cargando…

Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center

BACKGROUND: PCSK9 inhibitor therapy has been approved by the FDA as an adjunct to diet-maximal tolerated cholesterol lowering drug therapy for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) with suboptimal LDL cholesterol (LDL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shah, Parth, Glueck, Charles J., Jetty, Vybhav, Goldenberg, Naila, Rothschild, Matan, Riaz, Rashid, Duhon, Gregory, Wang, Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991071/ https://www.ncbi.nlm.nih.gov/pubmed/27538393 http://dx.doi.org/10.1186/s12944-016-0302-8

Ejemplares similares

Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dl despite maximal tolerated cholesterol lowering therapy
por: Glueck, Charles J., et al.
Publicado: (2016)

Associations between Serum 25-hydroxyvitamin D and Lipids, Lipoprotein Cholesterols, and Homocysteine
por: Glueck, Charles J., et al.
Publicado: (2016)

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy
por: Jetty, Vybhav, et al.
Publicado: (2017)

Safety of 50,000-100,000 Units of Vitamin D3/Week in Vitamin D-Deficient, Hypercholesterolemic Patients with Reversible Statin Intolerance
por: Jetty, Vybhav, et al.
Publicado: (2016)

Hospitalization for pulmonary embolism associated with antecedent testosterone or estrogen therapy in patients found to have familial and acquired thrombophilia
por: Prince, Marloe, et al.
Publicado: (2016)

Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study
por: Shah, Parth, et al.
Publicado: (2017)

Four Thrombotic Events Over 5 Years, Two Pulmonary Emboli and Two Deep Venous Thrombosis, When Testosterone-HCG Therapy Was Continued Despite Concurrent Anticoagulation in a 55-Year-Old Man With Lupus Anticoagulant
por: Glueck, Charles J., et al.
Publicado: (2016)

Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice
por: Yamamoto, Tsuyoshi, et al.
Publicado: (2012)

Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study
por: Choi, Joshua, et al.
Publicado: (2017)

Management of High-Risk Hypercholesterolemic Patients and PCSK9 Inhibitors Reimbursement Policies: Data from a Cohort of Italian Hypercholesterolemic Outpatients
por: Fogacci, Federica, et al.
Publicado: (2022)

Pharmacoeconomic considerations in the treatment of breast cancer
por: Pallis, Athanasios, et al.
Publicado: (2010)

Pharmacoeconomic evaluations in the treatment of actinic keratoses
por: Tolley, Keith, et al.
Publicado: (2017)

Treatment with PCSK9 Inhibitor Evolocumab Improves Vascular Oxidative Stress and Arterial Stiffness in Hypercholesterolemic Patients with High Cardiovascular Risk
por: Silla, Alessia, et al.
Publicado: (2023)

Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk
por: Goldenberg, Naila, et al.
Publicado: (2009)

In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model
por: Carreras, Alba, et al.
Publicado: (2019)

Cholesterol-Lowering Effect of Allicin on Hypercholesterolemic ICR Mice
por: Lu, Yin, et al.
Publicado: (2012)

Krill Oil Inhibits Cholesterol Synthesis and Stimulated Cholesterol Excretion in Hypercholesterolemic Rats
por: Kim, Ok-Kyung, et al.
Publicado: (2022)

Pharmacoeconomic aspects of the treatment of pituitary gland tumours
por: Sowiński, Jerzy, et al.
Publicado: (2013)

Anti-hypercholesterolemic Effect of Berbamine Isolated from Rhizoma Coptidis in Hypercholesterolemic Zebrafish Induced by High-Cholesterol Diet
por: Han, Bing, et al.
Publicado: (2018)

Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects
por: Yokote, Koutaro, et al.
Publicado: (2019)

Coronary microcirculatory dysfunction in hypercholesterolemic patients with COVID-19: potential benefit from cholesterol-lowering treatment
por: Vuorio, Alpo, et al.
Publicado: (2023)

Retinal vascular occlusion: a window to diagnosis of familial and acquired thrombophilia and hypofibrinolysis, with important ramifications for pregnancy outcomes
por: Dixon, Stephan G, et al.
Publicado: (2016)

Essentials of pharmacoeconomics
por: Rascati, Karen L.
Publicado: (2014)

Principles of pharmacoeconomics /
Publicado: (1996)

A review of the pharmacoeconomics of eletriptan for the acute treatment of migraine
por: Bhambri, Rahul, et al.
Publicado: (2015)

Functional Characterization of p.(Arg160Gln) PCSK9 Variant Accidentally Found in a Hypercholesterolemic Subject
por: Larrea-Sebal, Asier, et al.
Publicado: (2023)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

Testosterone Therapy, Thrombophilia, Venous Thromboembolism, and Thrombotic Events
por: Glueck, Charles J., et al.
Publicado: (2018)

Cholesterol-Related lncRNAs as Response Predictors of Atorvastatin Treatment in Chilean Hypercholesterolemic Patients: A Pilot Study
por: Paez, Isis, et al.
Publicado: (2023)

Haemophilia A: Pharmacoeconomic Review of Prophylaxis Treatment versus On-Demand
por: Unim, Brigid, et al.
Publicado: (2015)

Pharmacoeconomics of genotyping-based treatment decisions in patients with chronic pain
por: Morlock, Robert, et al.
Publicado: (2017)

Pharmacoeconomic evaluation of treatment effectiveness with selected biologic treatment in rheumatoid arthritis therapy
por: Kowalik, Krzysztof, et al.
Publicado: (2018)

Effect of a PCSK9 inhibitor and a statin on cholesterol efflux capacity: A limitation of current cholesterol‐lowering treatments?
por: Ying, Qidi, et al.
Publicado: (2022)

Beneficial Effects of Indigenous Probiotics in High-Cholesterol Diet-Induced Hypercholesterolemic Rats
por: Puttarat, Narathip, et al.
Publicado: (2023)

Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina
por: Elgart, Jorge F, et al.
Publicado: (2013)

Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
por: Castrop, Florian, et al.
Publicado: (2013)

Pharmacoeconomic evaluation of costs of rheumatoid arthritis therapy with selected biological treatment
por: Kowalik, Krzysztof, et al.
Publicado: (2018)

Need for pharmacoeconomic consideration of antiepileptic drugs monotherapy treatment in persons with epilepsy
por: Sarangi, Sudhir C., et al.
Publicado: (2020)

The pharmacoeconomics of the state-of-the-art drug treatments for asthma: a systematic review
por: Menzella, Francesco, et al.
Publicado: (2021)

Pharmacoeconomics in COPD: lessons for the future
por: Starkie, Helen J, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_oag0a2nej05etuub735h14miom